Alcedis - a HUMA company

How will #AI, regulatory shifts, and new research models shape the future of pharmaceutical medicine in Germany? Last week, our colleagues Sarah Miethe and Kathrin Wolz attended #DGPharMed, the annual Congress for Pharmaceutical Medicine in Berlin, to explore the latest developments. The event featured many insightful sessions, from the opening keynote by Matthias Meergans on Germany’s innovation framework for 2035 to a 360-degree panel discussion on strengthening Germany as a #research hub. Dr. Meergans' keynote provided a compelling vision for the future, highlighting the collective responsibility of industry, academia, and regulators in driving innovation. The panel discussion reinforced this perspective, offering a frank assessment of the challenges in clinical research—particularly around feasibility strategies, site performance, and digital transformation. Our colleagues were especially impressed by Dr. Agnes Musiol’s insights, which provided valuable perspectives on the evolving research landscape, and Dr. Klaus-Gustav Beinhauer skillful moderation. The consensus? Germany has immense potential, but unlocking it will require collaboration, agility, and forward-thinking regulation. It was inspiring to see industry leaders, regulators, and researchers come together to drive progress in pharmaceutical medicine. We’re eager to integrate these insights into our work and continue advancing clinical research. 💡 What’s your perspective on recent developments in clinical trials? We’d love to hear your thoughts in the comments!  Deutsche Gesellschaft für Pharmazeutische Medizin e.V. (DGPharMed)

Last week at #ATTD2025 in #Amsterdam, we explored the future of diabetes care and how digitized data is transforming both patient care and clinical research. Discussions focused on AI-driven decision-making, next-generation measurement technologies, and groundbreaking advancements in type 1 diabetes treatment. Key innovations included curative treatment strategies, advanced glucose sensors, closed-loop systems, and novel insulin delivery methods—highlighting the rapid progress in diabetes prevention and therapy. A standout initiative was Sanofi’s campaign for earlier type 1 diabetes testing. Attendees could undergo fingertip autoantibody testing, which helps identify individuals at risk. The presence of two or more autoantibodies signals an inevitable progression at some point in life. Despite its importance, such screening programs are not yet available in Germany. As a hands-on experiment, our two attendees, Dr. Benedikt Linder and Edith Giemula, are now testing Abbott’s latest CGM devices, which were provided for trial use during the event. Thank you Advanced Technologies & Treatments for Diabetes (ATTD) for three inspiring days! #ATTD #ClinicalTrials

As #BIOEuropeSpring in Milan comes to an end, and I wait for my flight home, it’s the perfect time to reflect on three dynamic days filled with inspiring conversations and insights. We had the opportunity to engage with +40 biotech companies, each striving to navigate the complex path of clinical development. Some will successfully bring their innovations to patients, while others may face significant challenges. At Alcedis - a HUMA company, we look forward to supporting some of them as a trusted partner on their journey. The variety of treatment options is growing at an unprecedented pace, fueled by innovation in science and AI-driven drug discovery. This rapid evolution will shape future BIO events, intensifying competition - especially in financing, which is a critical challenge. While much of the discussion focused on oncology and neurology, it was clear that ophthalmology is on the rise. Given our extensive experience in this field over the past years, I am excited to see how this therapeutic area continues to evolve. Looking forward to continued collaborations and our journey ahead! #BioEuropeSpring #Biotech #ClinicalDevelopment #Oncology #Neurology #Ophthalmology

Over the past month, we had the privilege of visiting the three organizations that received donations from our annual Christmas charity game: 🎗 Elternverein für Leukämie- und krebskranke Kinder Gießen e.V. (Parents’ Association for Children with Leukemia and Cancer in Gießen) 🎗 Rexrodt von Fircks Stiftung (Rexrodt von Fircks Foundation – For Mothers with Cancer and Their Children) 🐾 Tierschutzverein Gießen und Umgebung e.V. (Animal Welfare Association Gießen and Surroundings) Every visit was filled with inspiring and insightful conversations. Our time at the children's ward, in particular, was a powerful reminder of why our work in clinical research matters. Seeing the real-life impact on patients and their families reinforces our commitment to advancing medical research. A huge thank you to everyone who participated in our Christmas charity campaign—whether you’ve been part of it for years or joined for the first time in 2024. Your engagement made this impact possible! If you’d like to support these organizations yourself, we encourage you to visit their websites and learn more about their incredible work. Let’s continue making a difference together. ❤️ Huma Bernhard Remes Hanno Härtlein Alex Heinz Diana Zanger Jens Hansen Frank Morneweg Rexrodt von Fircks Stiftung für krebskranke Mütter und ihre Kinder #ThankYou #MakingADifference #Charity

Meet us at #BioEuropeSpring next week in #Milan, Italy. 👇 The #biotech landscape is evolving rapidly. As a key event for biotech and pharma leaders, the internationally recognized conference is looking to push the boundaries of innovation and showcasing emerging technologies that will shape the next generations of life science. Hanno Härtlein and Dr. Benedikt Linder, are looking forward to insightful discussions, discovering new opportunities, and building strategic partnerships for future collaborations in biotech. Contact us for a meeting at the following link, if you are attending as well: ➡️ https://lnkd.in/gvH3tmYD #LifeSciences #ClinicalTrials

Interesting #paper on AstraZeneca-funded real-world study on AI-based early detection of incidental pulmonary nodules. The retrospective study, DETECT IPN, investigated the precision of two AI-based, computer-aided IPN detection systems at three German radiological centers (Heidelberg, Hanover and Munich), and collected data within clinical routine at the respective centers in 2021 over an observation period of 12 months. 🔗https://lnkd.in/e_NiHr7W Johannes Dunsche, Hans-Ulrich Kauczor, Oyunbileg V. Stackelberg, PD Dr. med. Isabelle Ayx, Rimma Kondrashova, Jens Vogel-Claussen, Joana Lamché, PD Dr. Gerald Schmid-Bindert #DETECTIPN #Publication #ClinicalTrials

For a very long time, #women were underrepresented in clinical trials, resulting in predominantly male-centered research and drug development. Physiological and biological differences, combined with sociocultural factors, create major challenges and limitations for women in #healthcare worldwide. These disparities not only affect diagnosis and treatment but also influence access to medical research and innovation. To address this problem, clinical research must specifically adapt appropriate recruitment and study designs, as well as differentiated data analyses. Explore important factors and challenges surrounding this issue in our latest #blog article: ➡️ https://lnkd.in/eSkh9M-4 #InternationalWomensDay #Gender #ClinicalTrials

We sent Mareike Susann Poetsch, PhD to the 26th European Congress on Gynaecological Oncology (#ESGO), and she came back with some really valuable learnings! With over 50 scientific sessions, the congress provided invaluable insights into the latest medical and scientific advancements in gynecological cancer research, treatment, and care. A key focus for us was ovarian cancer, where we were able to deepen our expertise. Additionally, we gained valuable insights into the evolving treatment landscape for endometrial carcinoma (EC)—especially regarding how to improve outcomes in pMMR EC by addressing disease complexity and emerging treatment options. Other key highlights included: - Presentation of the new ESGO-ESTRO-ESP Guidelines on the Management of Endometrial Carcinoma, including patient perspectives - Exciting discussions on "New emerging pathways and targeted treatments in gynecological cancers", with a particular focus on the role of ADCs (antibody-drug conjugates) in treatment - Insights into the challenges of treating adolescents and young adults with cancer - A 3.5-hour live surgery session A truly inspiring congress, filled with meaningful discussions! European Society of Gynaecological Oncology #GynecologicOncology #WomensHealth #ClinicalTrials #ESGO2025

Join us at #ATTD2025 on March 19-22, 2025, in beautiful #Amsterdam. 👋 We are excited to participate in this prestigious global conference, where clinicians, researchers, industry leaders, and regulators come together to drive innovation and accelerate progress in #diabetes care. This year’s program will showcase groundbreaking advancements, including AI-driven decision support systems, glucose sensors, closed-loop systems, artificial pancreas technology, and novel insulin delivery methods. As a CRO, we are looking forward to insightful discussions, exploring the latest research, and forging valuable collaborations to advance clinical development in diabetes care. Connect with Dr. Benedikt Linder and Edith Giemula during the event. Hope to see you there! Advanced Technologies & Treatments for Diabetes (ATTD) #ATTD #ClinicalTrials

Mark your calendar for our #webinar on "𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝟮𝟬𝟮𝟱: 𝗔𝗿𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻 𝗚𝗲𝗿𝗺𝗮𝗻𝘆 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗺𝗼𝗿𝗲 𝗮𝘁𝘁𝗿𝗮𝗰𝘁𝗶𝘃𝗲?" on March 12, 2025. 🗓️ Join our speakers Sascha Herzer and Birgit von Buttlar-Brandenfels for a deep dive into recent #regulatory changes in Germany's clinical research landscape. From extended data access and accelerated approvals to new funding frameworks, this webinar will explore the most impactful regulatory updates of the past and upcoming year. Are these changes fostering innovation or introducing new complexities? Hanno Härtlein Bernhard Remes Dr. Marc Hetzel #ClinicalResearch #ClinicalTrials